# GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

> **NCT07122076** · EARLY_PHASE1 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 10 (estimated)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** GT719 Injection

## Key facts

- **NCT ID:** NCT07122076
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-22
- **Primary completion:** 2028-08-21
- **Final completion:** 2028-08-21
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07122076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07122076, "GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07122076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*